Lower probability of persistence of total anti-SARS-CoV-2 antibodies after COVID-19 among people living with HIV

Affiliations

• ¹ Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Seville, Spain; Department of Medicine, School of Medicine, Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain; CIBERINFEC, Spain.
• ² Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Seville, Spain; Department of Medicine, School of Medicine, Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.
• ³ Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Seville, Spain.
• ⁴ Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Seville, Spain; Department of Surgery, Biochemistry and Immunology, School of Medicine, University of Malaga, Malaga, Spain; CIBERINFEC, Spain. Electronic address: lmreal67b@gmail.com.
• ⁵ Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Seville, Spain; Department of Surgery, Biochemistry and Immunology, School of Medicine, University of Malaga, Malaga, Spain; CIBERINFEC, Spain.